ESSA Pharma Inc. (EPIX) Receives Consensus Rating of “Buy” from Brokerages

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has been given a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company.

Analysts have set a 1 year consensus target price of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 111 out of 265 based on the ratings given to its competitors.

A number of analysts have issued reports on EPIX shares. Bloom Burton downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Zacks Investment Research downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, October 3rd.

Shares of ESSA Pharma (EPIX) traded up $0.01 on Thursday, reaching $0.21. The company had a trading volume of 30,616 shares, compared to its average volume of 82,087. The company has a debt-to-equity ratio of -1.32, a current ratio of 1.26 and a quick ratio of 1.26. ESSA Pharma has a 52 week low of $0.15 and a 52 week high of $3.59. The company has a market cap of $5.75, a P/E ratio of -1.31 and a beta of 2.09.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/24/essa-pharma-inc-epix-receives-consensus-rating-of-buy-from-brokerages.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit